R1 Therapeutics has formed a scientific advisory board comprising seven internationally recognised nephrology experts as the company prepares to advance AP306 into global phase 2b trials for hyperphosphatemia in chronic kidney disease.
The board is chaired by Glenn Chertow, Professor of Medicine, Epidemiology and Population Health, and Health Policy at Stanford University School of Medicine. R1 said the appointments come at a key moment as AP306, a first‑in‑class pan phosphate transporter inhibitor, progresses towards its next stage of clinical development.
The company said the addition of seven global leaders in nephrology provides strong external validation of its scientific approach. The experts will offer scientific, translational and clinical guidance as AP306 moves through development.
Krishna Polu, Co‑Founder, President and CEO of R1 Therapeutics, said: “Bringing together this caliber of scientific leadership is a major milestone for R1.”
“Their collective experience in advancing novel therapies through clinical development and their specific expertise in the field of CKD‑Mineral Bone Disorder and Dialysis will be instrumental as we progress AP306 into global phase 2b trials and beyond. Our shared ambition to improve outcomes for patients with chronic kidney disease will guide our work as we advance this program.”
Glenn Chertow, Chair of the scientific advisory board, said: “Hyperphosphatemia remains a persistent and under‑addressed challenge in the management of chronic kidney disease, with many patients unable to achieve adequate control with current therapies.”
“AP306 represents a genuinely novel approach by blocking the active transport of phosphate. I look forward to working with R1 and my fellow Board members to help translate this potential into meaningful benefits for patients.”
